Mechanisms of Resistance to CDK4/6 Inhibitors in Breast Cancer and Potential Biomarkers of Response.

about

Current Landscape of Targeted Therapies for Hormone-Receptor Positive, HER2 Negative Metastatic Breast Cancer

P2860

Q57108041-FB04F83C-A124-4919-9B46-5E4A14E8CABB

P2860

Mechanisms of Resistance to CDK4/6 Inhibitors in Breast Cancer and Potential Biomarkers of Response.

Item

http://www.wikidata.org/entity/Q47321016

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Mechanisms of Resistance to CD ...... ential Biomarkers of Response.

@en

Mechanisms of Resistance to CD ...... ential Biomarkers of Response.

@nl

type

Item

label

Mechanisms of Resistance to CD ...... ential Biomarkers of Response.

@en

Mechanisms of Resistance to CD ...... ential Biomarkers of Response.

@nl

prefLabel

Mechanisms of Resistance to CD ...... ential Biomarkers of Response.

@en

Mechanisms of Resistance to CD ...... ential Biomarkers of Response.

@nl

P1476

Mechanisms of Resistance to CD ...... tential Biomarkers of Response

@en

P2093

Cristina Guarducci

http://www.w3.org/2001/XMLSchema#string

Emanuela Risi

http://www.w3.org/2001/XMLSchema#string

Giulia Boccalini

http://www.w3.org/2001/XMLSchema#string

Ilenia Migliaccio

http://www.w3.org/2001/XMLSchema#string

Martina Bonechi

http://www.w3.org/2001/XMLSchema#string

P2860

PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro

The retinoblastoma family of proteins and their regulatory functions in the mammalian cell division cycle

Therapeutic CDK4/6 inhibition in breast cancer: key mechanisms of response and failure.

Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines.

CDK 4/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors.

The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.

APC/C and retinoblastoma interaction: cross-talk of retinoblastoma protein with the ubiquitin proteasome pathway

Brk/Protein tyrosine kinase 6 phosphorylates p27KIP1, regulating the activity of cyclin D-cyclin-dependent kinase 4

Cyclin D as a therapeutic target in cancer

Inhibitors of mammalian G1 cyclin-dependent kinases

P304

304-308

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

review article

P356

10.1159/000484167

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Angelo Di Leo

Matteo Benelli

Luca Malorni

P577

2017-10-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29234249

http://www.w3.org/2001/XMLSchema#string

P932

5704709

http://www.w3.org/2001/XMLSchema#string

Mechanisms of Resistance to CDK4/6 Inhibitors in Breast Cancer and Potential Biomarkers of Response.

about

P2860

P2860

Mechanisms of Resistance to CDK4/6 Inhibitors in Breast Cancer and Potential Biomarkers of Response.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932